Anita Nelson, MD, discusses the FDA's approval extending etonogestrel implant use to 5 years and the new REMS certification clinicians must complete by February 23, 2027.
|Articles|September 1, 2002
Condition-specific coding: the key to billing for U/S
Ob/gyn patients undergo ultrasounds for a number of reasons. Because of the small variety of closely related U/S codes, successful billing for more than one U/S depends on the diagnosis and documentation.
Advertisement
Advertisement
Related to this article
Placentas from older mothers held less NAD+, and in aged pregnant mice, nicotinamide riboside or the CD38 inhibitor 78c restored placental NAD+ and improved fetal growth.
Hugh Taylor, MD, outlines a stepwise approach to endometriosis therapy, from first-line oral contraceptives to oral GnRH antagonists for progestin-resistant patients.
Hosted by Calbeth C. Alaribe, DMSc, MPH, PA-C, CPCHE, the monthly series brings clinicians, researchers, innovators, advocates, and other voices across women’s health into conversations that rarely happen in the same room.
A new book from Sameena Rahman, MD, reclaims "brown girls' disease" as a lens for examining how dismissal—of conditions, anatomy, and patients—undermines sexual medicine care for all women.
Menopause proteomics were consistently associated with inflammatory brain aging and Alzheimer’s dementia risk across nearly 15,000 women in a new study published in Nature Medicine.
The FDA approved an IDE allowing Mercy BioAnalytics to evaluate its Evident blood-based ovarian cancer screening test in the prospective pivotal SOARA study of average-risk women.
Sameena Rahman, MD, discusses how digital symptom trackers can shorten PMOS diagnostic delays and support earlier cardiometabolic care.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
Contemporary OB/GYN launches 'Missed & Dismissed' podcast to explore diagnostic gaps in women's health
2
Menopause proteomic scores associated with cognitive aging, dementia risk
3
CD38 is tied to age-related placental NAD+ decline in preclinical study
4
Zuranolone shows sustained PPD symptom improvement through day 90
5